Gadolinium-Based MRI Agents Patents: Who Leads, Where Gaps Are 2026
Gadolinium-Based MRI Agents: Mapping the Patents Behind Contrast Imaging
16.3% concentration at the top. The five leading assignees hold 813 of 4,995 records in scope — a real lead, but nowhere near a lock on the field. Filings rose from 147 in 2017 to a peak of 189 in 2019, then eased. The 2021-to-2024 span — the last stretch that publication lag has fully caught up with — moved from 122 to 113 records, a 7% decline. Years after 2024 in the chart are undercounted because publication trails filing by roughly 18 months; treat 2025 and 2026 figures as provisional, not as evidence of a steeper drop.
- 1BRACCO IMAGING SPA6.9%
- 2BOARD OF RGT THE UNIV OF TEXAS SYST2.5%
- 3RGT UNIV OF CALIFORNIA2.4%
- 4GUERBET SA2.4%
- 5DYAX CORP2.1%
See the full gadolinium-based mri agents analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on gadolinium MRI agent patents
Who holds the most patents on gadolinium-based MRI contrast agents?
The leading assignee in this corpus holds 346 of the 4,995 records in scope, well ahead of the fifth-ranked assignee at 105. Together the top five assignees account for 813 records, or 16.3% of the field, and the top ten account for 25.4%. That leaves roughly three-quarters of the corpus spread across a long tail of universities, smaller imaging firms and single-filing entrants, so no one company controls the space outright.
Is gadolinium MRI contrast agent patent filing slowing down?
Filing moved from 122 records in 2021 to 113 in 2024, a 7% decline over that span, which is the most recent window where publication has largely caught up with filing activity. Numbers for 2025 and 2026 look lower still, but that reflects the roughly 18-month lag between filing and publication rather than a genuine drop. A plateau is a more accurate description than a slowdown based on the data available now.
What does US8901294B2 actually cover?
US8901294B2 claims a gadolinium complex built from a DO3A-tranexamic acid or ester compound, positioned as delivering higher relaxivity than the contrast agents commercially available when it was filed. It also claims bifunctionality suited to liver-targeted imaging, which narrows its practical scope to that specific chelate structure and its stated imaging application rather than gadolinium chelates generally. Anyone designing a competing liver-targeted agent should check this claim’s specific chemical scope before assuming it blocks a different chelate backbone.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Gadolinium-Based MRI Agents covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.